Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noribogaine is the principal psychoactive metabolite of ibogaine, formed via O-demethylation. It is a naturally occurring alkaloid found in plants of the Apocynaceae family, notably Tabernanthe iboga. Noribogaine exhibits complex pharmacology and is thought to be primarily responsible for many of the antiaddictive effects attributed to ibogaine-containing preparations. Mechanistically, it acts as a potent serotonin reuptake inhibitor and has higher affinity than its parent compound for both κ-opioid (KOR) and μ-opioid receptors, where it functions as a biased agonist at KOR (favoring G protein signaling over β-arrestin recruitment) and likely as a partial agonist or antagonist at μ-opioid receptors. Noribogaine also acts as a weak NMDA receptor antagonist and inhibits hERG potassium channels, which can lead to QT prolongation and cardiac arrhythmias. Its long half-life in humans (28–49 hours) may contribute to sustained effects on opioid withdrawal symptoms by modulating serotonergic and opioid systems[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on noribogaine.